What Due Diligence Misses, We Detect

What If the Real Risk Isn’t in the Numbers—But in the Behavior That Starts After the Signature?

Biopharma Business Intelligence Unit (BBIU) uncovers structural, operational, and behavioral risks in Korean biotech companies—especially those hidden beneath cultural dynamics like the Gap-Eul hierarchy, where power can shift dramatically post-agreement.

We specialize in identifying what others overlook:

• Governance opacity

• Data misalignment

• Post-signature behavioral shifts masked as “execution”

We don’t rely on dashboards. We rely on dissonance.

When the narrative, behavior, and numbers misalign—we act. Especially when hidden hierarchies, like Gap-Eul dynamics, distort post-deal collaboration.